Charles River's Strategic Investments and Financial Performance

Charles River has implemented a series of investment strategies, including acquisitions, technology partnerships, and internal development, to gain access to innovative technologies and expertise. Since 2012, the company has invested over $4.5 billion and acquired more than 25 companies to expand its scientific capabilities, enhance its global footprint, and ensure its leadership in advanced and emerging therapies.

To date, Charles River has established over 20 active collaborations with companies and institutions, and has invested more than $135 million in corporate partnerships and licensing. Recent strategic partnerships have focused on the antibody discovery capabilities of Distributed Bio (acquired), the label-free high-throughput screening (HTS) technology of SAMDI Tech (acquired), the digital pathology technology of Deciphex, the NGS-based biotherapeutic QC testing technology of PathoQuest, and the AI-driven drug discovery technology of Valo Health.

Charles River's collaboration with the biotechnology company Cypre has led to new advancements in the development of 3D cancer models that can simulate the complexity of the tumor and its surrounding tissues, enabling the identification of new therapeutic targets and supporting the research of next-generation cancer drugs. The partnership with Valo Health has helped in the early assessment of drug candidates using computational models to predict their efficacy, toxicity, and metabolism, reducing the reliance on animal studies. Cypre and Valo Health are both exemplars in the AMAP alternative program.

In addition to acquisitions and strategic collaborations, Charles River has also become the preferred partner for emerging biotechnology companies through venture capital (VC) investments, expanding its access to next-generation science and technology. In 2023, approximately 10% of Charles River's annual revenue came from VC-backed companies, with an average annual return rate of 25% from VC relationships (investments and revenues).

Charles River acquired 75% ownership of Vital River in 2013, entering the Chinese market (Vital River had been the sole authorized producer and animal model distributor for Charles River in mainland China for over a decade). Since then, Charles River has gradually expanded its drug research services in China, including microbial testing, biopharmaceutical testing, and the Cradl Accelerator Laboratory for new drugs.

In 2023, Charles River achieved total revenue of $4.13 billion, a 3.9% increase year-over-year. Its GAAP operating profit margin was 14.9%, down from 16.4% in 2022. GAAP net income attributable to common shareholders was $474.6 million, a 2.4% decrease year-over-year, and diluted earnings per share was $9.22, a 2.7% decrease.

In the first quarter of 2024, Charles River's total revenue was $1.01 billion, a 1.7% decrease year-over-year. Its GAAP operating profit margin was 12.5%, down from 16.3% in the same period last year. Net income attributable to common shareholders was $67.3 million, a 34.7% decrease year-over-year, and diluted earnings per share was $1.30, a 35.3% decrease.

According to Charles River's latest guidance, the company expects its 2024 full-year total revenue to grow by 1.0% to 4.0%, and GAAP earnings per share to be between $7.60 and $8.10.